Table 1 Clinicopathological features of advanced ovarian carcinomas with and without high-dose chemotherapy
From: Are there candidates for high-dose chemotherapy in ovarian carcinoma?
CCA | HDC | p -value | Odd or Hazard Ratio (95CI) | |||
|---|---|---|---|---|---|---|
N | N (%) | N (%) | ||||
103 | 60 | |||||
Follow-up (median, months) | 163 | 46.7 | 48.2 | 0.08*** | ||
Median Age (years) | 163 | 56,0 | 53,0 0 | 09*** | ||
Age | 163 | 0.73**** | 1.15 [0.55-2.45] | |||
≤50y | 34 (33) | 18 (30) | ||||
>50y | 69 (67) | 42 (70) | ||||
OMS | 117 | 0.17**** | 0.35 [0.06-1.37] | |||
0-1 | 63 (81) | 36 (92) | ||||
2-3 | 15 (19) | 3 (8) | ||||
FIGO | 163 | 0.33**** | 1.47 [0.63-3.39] | |||
IIIc | 84 (82) | 45 (75) | ||||
IV | 19 (18) | 15 (25) | ||||
Histological subtype | 163 | 0.62**** | 0.82 [0.40-1.65] | |||
Serous | 62 (60) | 39 (65) | ||||
Others | 41 (40) | 21 (35) | ||||
Grade | 98 | 0.01**** | 0.32 [0.12-0.81] | |||
1-2 | 19 (31) | 21 (58) | ||||
3 | 43 (69) | 15 (42) | ||||
Cytoreductive surgery | 160 | |||||
Complete | 56 (56) | 40 (67) | 0.24**** | 0.64 [0.31-1.30] | ||
residual disease | 44 (44) | 20 (33) | ||||
Clinical complete response* | 161 | |||||
Yes | 63 (62) | 50 (83) | 0.007**** | 0.33 [0.14-0.77] | ||
No | 38 (38) | 10 (17) | ||||
CA-125** | 149 | 0.66**** | 0.75 [0.27-1.92] | |||
Normal | 73 (80) | 49 (85) | ||||
>Normal | 18 (20) | 9 (15) | ||||
Time from end of initial CT to HDCT (median, months) | 61 | NA | 2.8 | NA | NA | |
Median PFS (months) | 18.1 | 20.1 | 0.09***** | |||
Median OS (months) | 41.3 | 47.3 | 0.24***** | |||